TI
MRNS

Trexquant Investment’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Trexquant Investment’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-107,533
Closed -$972K – 1940
2024
Q1 		$972K Buy
107,533
+56,682
+111% +$551K 0.02% 922
2023
Q4 		$553K Buy
+50,851
New +$381K 0.01% 1044
2023
Q1 		– Sell
-10,213
Closed -$40.6K – 1861
2022
Q4 		$40.6K Buy
+10,213
New +$50.2K ﹤0.01% 1325
2022
Q2 		– Sell
-35,738
Closed -$334K – 1956
2022
Q1 		$334K Buy
+35,738
New +$355K 0.02% 947
2021
Q4 		– Sell
-16,938
Closed -$193K – 1711
2021
Q3 		$193K Buy
+16,938
New +$233K 0.02% 966
2020
Q4 		– Sell
-24,442
Closed -$314K – 1591
2020
Q3 		$314K Buy
+24,442
New +$211K 0.02% 904
2018
Q3 		– Sell
-3,616
Closed -$102K – 1251
2018
Q2 		$102K Buy
+3,616
New +$80.2K 0.01% 836
2018
Q1 		– Sell
-7,059
Closed -$230K – 1453
2017
Q4 		$230K Buy
+7,059
New +$190K 0.03% 869

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Trexquant Investment's MRNS Position: Q2 2024 in Review

Trexquant Investment sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 107,533 shares — an estimated $972K sold.

Trexquant Investment first reported a position in MRNS in Q4 2017 and held it in 8 quarters. The position peaked at $972K in Q1 2024. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Trexquant Investment reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Trexquant Investment sold 107,533 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $972K.
  • Trexquant Investment first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 8 quarters.
  • Trexquant Investment's Marinus Pharmaceuticals, Inc position peaked at $972K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Trexquant Investment's 13F filing for Q2 2024, filed 13 Aug 2024.